Valuation: Armata Pharmaceuticals, Inc.

Market Cap 130M 116M 108M 97.49M 182M 12.36B 184M 1.29B 513M 6.47B 487M 477M 20.53B P/E 2026 *
-1.87x
P/E 2027 * -2.42x
Enterprise Value 130M 116M 108M 97.49M 182M 12.36B 184M 1.29B 513M 6.47B 487M 477M 20.53B EV / Sales 2026 *
30.5x
EV / Sales 2027 * 47.2x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-4.58%
1 week+8.17%
Current month-9.81%
1 month-12.43%
3 months-30.02%
6 months-66.09%
Current year-47.29%
1 week 3.03
Extreme 3.03
3.84
1 month 2.74
Extreme 2.745
4.07
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
14.98
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/4/26 Free

Director

51,280 0.1400%
14/3/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-5.01%+8.17%-33.67%+45.81% 130M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.16%+0.22%+27.10%+56.50% 44.75B
+2.43%-3.30%+17.94%+100.25% 41.62B
+0.78%-3.99%+220.65%+916.46% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.53%+0.53%+43.09%+150.07% 38.06B
Weighted average by Cap. +3.11%-0.29%+47.04%+160.31%

Financials

2026 *2027 *
Net sales 4.25M 3.81M 3.53M 3.19M 5.97M 405M 6.04M 42.15M 16.79M 212M 15.95M 15.61M 672M 2.75M 2.47M 2.28M 2.07M 3.86M 262M 3.91M 27.27M 10.86M 137M 10.32M 10.1M 435M
Net income -76.6M -68.73M -63.54M -57.55M -108M -7.3B -109M -760M -303M -3.82B -287M -281M -12.12B -72M -64.6M -59.72M -54.09M -101M -6.86B -102M -714M -284M -3.59B -270M -264M -11.39B
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
29/10/26 US$3.310 -5.16% 39,229
27/10/26 US$3.490 +1.16% 104,310
26/10/26 US$3.450 -5.22% 63,646
23/10/26 US$3.640 +5.51% 115,590
22/10/26 US$3.450 +12.75% 107,994
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.490USD
Average target price
17.50USD
Spread / Average Target
+401.43%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock